These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33964292)

  • 1. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
    Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
    MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
    Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
    MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling.
    Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A
    Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 11. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains.
    Siegemund M; Oak P; Hansbauer EM; Allersdorfer A; Utschick K; Winter A; Grasmüller C; Galler G; Mayer JP; Weiche B; Prassler J; Kontermann RE; Rothe C
    Front Pharmacol; 2021; 12():759337. PubMed ID: 34759826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.
    Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S
    MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
    Cho SY; Han J; Cha SH; Yoon SI
    Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.
    Jacobs SA; Gibbs AC; Conk M; Yi F; Maguire D; Kane C; O'Neil KT
    Protein Eng Des Sel; 2015 Oct; 28(10):385-93. PubMed ID: 26275855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
    Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
    Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
    Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
    J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life.
    Kang HJ; Kim HJ; Cha SH
    Immunol Lett; 2016 Jan; 169():33-40. PubMed ID: 26593745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
    Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
    J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.